Beyond lipids: Novel mechanisms for parenteral nutrition–associated liver disease. (6th February 2022)

• Record Type: Journal Article
• Authors: Wichman, Brittany E.; Nilson, Jamie; Govindan, Srinivas; Chen, Alan; Jain, Aditya; Arun, Varsha; Derdoy, Juana; Krebs, Joseph; Jain, Ajay K.
• Is Part Of: Nutrition in clinical practice. Volume 37:Number 2(2022)
• Page Start: 265
• Page End: 273
• Publication Date: 2022-02-06
• Subjects: enteral nutrition -- Farnesoid X receptor -- fibroblast growth factor‐19 -- intestinal failure -- liver disease -- parenteral nutrition; Nutrition -- Periodicals; Diet therapy -- Periodicals; Artificial feeding -- Periodicals; 615.854
• DOI: 10.1002/ncp.10830
• Languages: English
• ISSNs: 0884-5336

Abstract

Abstract: Parenteral nutrition (PN) is a therapy that delivers essential nutrients intravenously to patients who are unable to meet their nutrition requirements via standard enteral feeding. This methodology is often referred to as PN when accompanied by minimal or no enteral nutrition (EN). Although PN is lifesaving, significant complications can arise, such as intestinal failure–associated liver disease and gut‐mucosal atrophy. The exact mechanism of injury remains ill defined. This review was designed to explore the available literature related to the drivers of injury mechanisms. The Farnesoid X receptor and fibroblast growth factor 19 signaling pathway seems to play an important role in gut‐systemic signaling, and its alteration during PN provides insights into mechanistic links. Central line infections also play a key role in mediating PN‐associated injury. Although lipid reduction strategies, as well as the use of multicomponent lipid emulsions and vitamin E, have shown promise, the cornerstone of preventing injury is the early establishment of EN.